Anupam Rama

Biren Amin

Cory Kasimov

Greg Harrison

Mani Foroohar

Paul Choi

Salim Syed

Tyler Van Buren

Andrew Tsai

Eliana Merle

Jason Zemansky

- BridgeBio Pharma presented data from the ATTRibute-CM study showing that **acoramidis reduced cumulative cardiovascular outcomes** in patients with ATTR-CM, with numerically fewer events observed within the first month of treatment.  **[1743881_9630616b08364285834b90a5c64d1096_0]** 
- Acoramidis significantly reduced the cumulative risk of cardiovascular mortality or recurrent cardiovascular-related hospitalizations through Month 30 versus placebo with a **49% hazard reduction**.  **[1743881_9630616b08364285834b90a5c64d1096_0]** 
- At Month 30, **53 events were avoided per 100 treated participants**, and at Month 42, cardiovascular mortality was reduced by **45%** with continuous acoramidis.  **[1743881_9630616b08364285834b90a5c64d1096_0]** 
- Acoramidis is approved as **Attruby® by the U.S. FDA** and as BEYONTTRA® by European, Japanese, and UK regulatory agencies for the treatment of ATTR-CM.  **[1743881_9630616b08364285834b90a5c64d1096_2]**

BridgeBio Pharma presents positive ATTRibute-CM study data for acoramidis

- BridgeBio provided updates on its **ADH-1 (encaleret)** program, detailing the **global Phase 3 study** across **25+ sites** and aiming for a **majority of patients to respond** to the drug, building on the **70% response rate** from Phase 2.  **[1743881_tx_380160_0]** **[1743881_tx_380160_1]** 
- For **418 (LGMD2i)**, the company is confident in replicating Phase 2 trends in the larger Phase 3 study, with interim analysis for accelerated approval based on **robust biomarker effects** (e.g., glycosylated alpha-dystroglycan).  **[1743881_tx_380160_3]** **[1743881_tx_380160_4]** 
- The commercial launch of **acoramidis (Trudy)** is progressing well, with **3,751 patients prescribed** as of **August 1** and a continuous increase in **treatment-naive patients**.  **[1743881_tx_380160_5]** **[1743881_tx_380160_6]**  The company expects **stable gross-to-net** in the **30%-40% range** and emphasizes its competitive advantages, including a **10% lower list price** and **best-in-class hospitalization data**.  **[1743881_tx_380160_6]** **[1743881_tx_380160_7]** 
- BridgeBio also discussed **infigratinib**, highlighting its **clean safety profile** and **best-in-class efficacy** from Phase 2, with the ongoing Phase 3 trial enrolling children **three and up**.  **[1743881_tx_380160_7]** **[1743881_tx_380160_8]**

BridgeBio Pharma Provides Updates on Pipeline and Commercial Execution at Wells Fargo Conference

- BridgeBio Pharma's acoramidis demonstrated a **statistically significant 44% hazard reduction** in cardiovascular mortality (CVM) through **42 months** in the ATTRibute-CM open label extension study.  **[1743881_7611ac5f9f32462e8708fd89fc902484_0]** 
- The study also showed a **46% hazard reduction** in the composite outcome of CVM or first cardiovascular hospitalization (CVH) through 42 months.  **[1743881_7611ac5f9f32462e8708fd89fc902484_0]** 
- Acoramidis treatment led to higher rates of disease stabilization or improvement versus disease progression, as reflected in NT-proBNP and NAC Stage changes, with benefits observed as early as **3 months**.  **[1743881_7611ac5f9f32462e8708fd89fc902484_0]** **[1743881_7611ac5f9f32462e8708fd89fc902484_1]** 
- Acoramidis is approved as Attruby® by the U.S. FDA and as BEYONTTRA® by the European Commission, Japanese Pharmaceuticals and Medical Devices Agency, and UK Medicines and Healthcare Products Regulatory Agency.  **[1743881_7611ac5f9f32462e8708fd89fc902484_0]** **[1743881_7611ac5f9f32462e8708fd89fc902484_2]**

BridgeBio Pharma Presents Positive Acoramidis ATTRibute-CM Study Results

BridgeBio Pharma (BBIO)